SG11201610349SA - Dosing regimens for treating and/or preventing cerebral amyloidoses - Google Patents

Dosing regimens for treating and/or preventing cerebral amyloidoses

Info

Publication number
SG11201610349SA
SG11201610349SA SG11201610349SA SG11201610349SA SG11201610349SA SG 11201610349S A SG11201610349S A SG 11201610349SA SG 11201610349S A SG11201610349S A SG 11201610349SA SG 11201610349S A SG11201610349S A SG 11201610349SA SG 11201610349S A SG11201610349S A SG 11201610349SA
Authority
SG
Singapore
Prior art keywords
treating
dosing regimens
preventing cerebral
cerebral amyloidoses
amyloidoses
Prior art date
Application number
SG11201610349SA
Other languages
English (en)
Inventor
Brandon Alan Wustman
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of SG11201610349SA publication Critical patent/SG11201610349SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201610349SA 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses SG11201610349SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461979408P 2014-04-14 2014-04-14
US14/684,967 US9675627B2 (en) 2014-04-14 2015-04-13 Dosing regimens for treating and/or preventing cerebral amyloidoses
PCT/US2015/025733 WO2015160796A1 (en) 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses

Publications (1)

Publication Number Publication Date
SG11201610349SA true SG11201610349SA (en) 2017-01-27

Family

ID=53015935

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610349SA SG11201610349SA (en) 2014-04-14 2015-04-14 Dosing regimens for treating and/or preventing cerebral amyloidoses

Country Status (10)

Country Link
US (2) US9675627B2 (enExample)
EP (1) EP3131547A1 (enExample)
JP (1) JP6662789B2 (enExample)
KR (1) KR20170003576A (enExample)
CN (1) CN107148270A (enExample)
AU (1) AU2015247859B2 (enExample)
CA (1) CA2945707A1 (enExample)
HK (1) HK1243643A1 (enExample)
SG (1) SG11201610349SA (enExample)
WO (1) WO2015160796A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2490712T3 (pl) * 2009-10-19 2015-12-31 Amicus Therapeutics Inc Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz
US9994589B2 (en) 2015-12-14 2018-06-12 Amicus Therapeutics, Inc. Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
CA2526173A1 (en) 2003-05-22 2004-12-02 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
CN104771402A (zh) 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
PL2533050T6 (pl) * 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
AU2007260812B2 (en) 2006-06-23 2012-08-16 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
US9056101B2 (en) 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2011011181A1 (en) 2009-07-01 2011-01-27 Amicus Therapeutics, Inc. Pharmacological chaperones for the treatment of alzheimer's disease
PL2490712T3 (pl) 2009-10-19 2015-12-31 Amicus Therapeutics Inc Sposób leczenia choroby Alzheimera przy zastosowaniu chaperonów farmakologicznych dla zwiększenia aktywności gangliozydaz
SG193379A1 (en) * 2011-03-11 2013-10-30 Amicus Therapeutics Inc Dosing regimens for the treatment of fabry disease
BR112014014808A2 (pt) * 2011-12-22 2018-09-25 Centogene Ip Gmbh combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação
PT2844279T (pt) * 2012-05-03 2021-03-11 Amicus Therapeutics Inc Esquema posológico para o tratamento da doença de pompe

Also Published As

Publication number Publication date
AU2015247859A1 (en) 2016-12-01
US9675627B2 (en) 2017-06-13
EP3131547A1 (en) 2017-02-22
JP6662789B2 (ja) 2020-03-11
US20170273996A1 (en) 2017-09-28
CN107148270A (zh) 2017-09-08
US20160008383A1 (en) 2016-01-14
JP2017511372A (ja) 2017-04-20
CA2945707A1 (en) 2015-10-22
HK1243643A1 (zh) 2018-07-20
WO2015160796A1 (en) 2015-10-22
KR20170003576A (ko) 2017-01-09
AU2015247859B2 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
IL252631A0 (en) Activin-actrii antagonists and uses for the treatment of anemia
SG11201609734VA (en) Devices and methods for treating lower extremity vasculature
IL250685A0 (en) Medicinal substance induces cytotoxicity
AU362358S (en) Pet treat
SI3215147T1 (sl) Nevroatenuacijske spojine norketamina in postopki
GB201502084D0 (en) Catheter devices and related methods
IL250045A0 (en) Methods for the treatment or prevention of ophthalmological conditions
LT3189074T (lt) Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai
IL251660A0 (en) A method for measured dosage and a mechanism for its application
IL251107A0 (en) Compounds and methods
IL251616A0 (en) Methods and compounds for the treatment and prevention of muscle loss
PL3186013T3 (pl) Urządzenie do obróbki przedmiotów
IL252904A0 (en) Methods and factors for treating diseases
ZA201703771B (en) Compositions and methods for treating hyperkalemia
IL250114A0 (en) Methods and compositions for the treatment of hiv-related diseases
GB201604707D0 (en) Elevator exclusive usage method and device
SG11201610349SA (en) Dosing regimens for treating and/or preventing cerebral amyloidoses
IL255012A0 (en) Preparations and methods for treating skin conditions
IL246637A0 (en) Preparations and methods for the treatment of intracerebral hemorrhage
GB201400311D0 (en) Treating Susceptibility
IL248506A0 (en) Dosage regimens of nitisinone for the treatment of alkeptonuria
SG11201804140PA (en) Acidic-gas treating agent and acidic-gas treating method
HUP1600390A2 (hu) Kumulatív hatású páncéltörõ eszközök hatásának fokozása megfelelõ robbanóanyag és bélésanyag alkalmazásával és ilyen anyagok
ZA201509077B (en) Safety net
GB201407949D0 (en) Compositions and methods for treating biofilms